Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges.
Adam Friedman, MD, FAAD, The George Washington School of Medicine & Health Sciences
Advertisement
Articles by Adam Friedman, MD, FAAD, The George Washington School of Medicine & Health Sciences
A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.
Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.
An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.
Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.
Advertisement
Latest Updated Articles
How to Discourage Non-Medical SwitchingMarch 26th 2021
Why and How Non-Medical Therapeutic Switching OccursMarch 19th 2021
COVID-19 and Payor Strategies for Non-Medical SwitchingApril 2nd 2021
Impact of Non-Medical Switching on the PatientMarch 26th 2021
Non-Medical Switching of Biosimilars and GenericsMarch 19th 2021
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
5